Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Эффективность применения низкокалорийных диет для лечения пациентов с ожирением
Эффективность применения низкокалорийных диет для лечения пациентов с ожирением
Трошина Е.А., Комшилова К.А., Силина Н.В., Ершова Е.В., Дзгоева Ф.Х. Эффективность применения низкокалорийных диет для лечения пациентов с ожирением. Consilium Medicum. 2024;26(4):251–256.
DOI: 10.26442/20751753.2024.4.202768
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
DOI: 10.26442/20751753.2024.4.202768
DOI: 10.26442/20751753.2024.4.202768
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
DOI: 10.26442/20751753.2024.4.202768
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Ожирение представляет собой многофакторную патологию, ассоциированную с комплексом метаболических нарушений, что обусловливает высокую социальную значимость данной патологии. Основную роль в снижении массы тела занимают диетологические рекомендации – снижение калорийности рациона питания, в связи с чем в настоящее время уделяется большое внимание эффективным программам снижения массы тела. Крайне важно не только назначать медикаментозную терапию по поводу имеющихся нарушений обмена веществ, но и как можно раньше рекомендовать пациенту рациональную низкокалорийную диету для эффективного и безопасного снижения массы тела. Данные многочисленных исследований демонстрируют эффективность применения низкокалорийных и очень низкокалорийных диет в лечении ожирения, соблюдение которых у пациентов часто вызывает определенные трудности, обусловленные необходимостью сохранения нутритивной ценности рациона и сбалансированного подбора макро- и микронутриентов. Длительное применение редуцированных диет может привести к развитию гиповитаминозов, недостатку пищевых волокон или снижению потребления белка. В 2024 г. на российском рынке появился новый продукт сбалансированного низкокалорийного питания ОПТИФАСТ (OPTIFAST®, компания Nestlé Health Science, Германия), который обеспечивает пациента всеми необходимыми питательными веществами и позволяет управлять суточным калоражем, дает пациенту чувство сытости, необходимое для высокой приверженности низкокалорийной диете, что обеспечивает эффективное и безопасное снижение массы тела преимущественно за счет жировой ткани.
Ключевые слова: ожирение, сахарный диабет, низкокалорийные диеты, ОПТИФАСТ
Keywords: obesity, diabetes mellitus, low-calorie diets, OPTIFAST
Ключевые слова: ожирение, сахарный диабет, низкокалорийные диеты, ОПТИФАСТ
________________________________________________
Keywords: obesity, diabetes mellitus, low-calorie diets, OPTIFAST
Полный текст
Список литературы
1. Здравоохранение в России. 2023: Стат. сб. Росстат. М., 2023. Режим доступа: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf. Cсылка активна на 25.04.2024 [Zdravookhranenie v Rossii. 2023: Stat. sb. Rosstat. Moscow, 2023. Available at: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf. Accessed: 25.04.2024 (in Russian)].
2. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12 [Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104-12 (in Russian)]. DOI:10.14341/DM2004116-17
3. WHO European Childhood Obesity Surveillance Initiative (COSI). Available at: https://www.who.int/europe/initiatives/who-european-childhood-obesity-surveillance-initiative-(cosi). Accessed: 25.04.2024.
4. World Obesity Federation. World obesity atlas 2022. London: World Obesity Federation, 2022.
5. Ley SH, Ardisson KAV, Sun Q, et al. Contribution of the Nurses’ Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016;106(9):1624-30. DOI:10.2105/AJPH.2016.303314
6. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., и др. Ожирение. Клинические рекомендации. Consilium Medicum. 2021;23(4):311-25 [Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311-25 (in Russian)]. DOI:10.26442/20751753.2021.4.200832
7. Министерство здравоохранения РФ. Методические руководства. Стандарты лечебного питания. M., 2017 [Ministerstvo zdravookhraneniia RF. Metodicheskiie rukovodstva. Standarty lechebnogo pitaniia. Moscow, 2017 (in Russian)].
8. Ley SK, Andres S, Qi T, et al. Contribution of the Nurses’ Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016;106:e1-e7. DOI:10.2105/AJPH.2016.303314.
9. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521. DOI:10.3389/fendo.2023.1161521
10. Czech MP. Mechanisms of insulin resistance related to white, beige, and brown adipocytes. Mol Metab. 2020;34:27-42. DOI:10.1016/j.molmet.2019.12.014
11. Tao C, Holland WL, Wang QA, et al. Short-term versus long-term effects of adipocyte toll-like receptor 4 activation on insulin resistance in Male mice. Endocrinology. 2017;158(5):1260-70. DOI:10.1210/en.2017-00024
12. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys. 2003;419(2):101-9. DOI:10.1016/j.abb.2003.08.020
13. Frakes AE, Dillin A. The UPR: sensor and coordinator of organismal homeostasis. Mol Cell. 2017;66(6):761-71. DOI:10.1016/j.molcel.2017.05.031
14. Lalia AZ, Lanza IR. Insulin-sensitizing effects of omega-3 fatty acids: lost in translation? Nutrients. 2016;8(6):329. DOI:10.3390/nu8060329
15. Frost G, Sleeth ML, Sahuri-Arisoylu M, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611. DOI:10.1038/ncomms4611
16. Neinast M, Murashige D, Arany Z. Branched chain amino acids. Annu Rev Physiol. 2019;81:139-64. DOI:10.1146/annurev-physiol-020518-114455
17. Siddik MAB, Shin AC. Recent progress on branched-chain amino acids in obesity, diabetes, and beyond. Endocrinol Metab (Seoul Korea). 2019;34(3):234-46. DOI:10.3803/EnM.2019.34.3.234
18. Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535(7612):376-81. DOI:10.1038/nature18646
19. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541-6. DOI:10.1038/nature12506
20. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2017;2(10):747-56.
DOI:10.1016/S2468-1253(17)30147-4.
21. Grasset E, Burcelin R. The gut microbiota to the brain axis in the metabolic control. Rev Endocr Metab Disord. 2019;20(4):427-38. DOI:10.1007/s11154-019-09511-1.
22. Mustajoki P, Pekkarinen T. Very low energy diets in the treatment of obesity. Obes Rev. 2001;2(1):61-72.
23. Ard JD, Lewis KH, Rothberg A, et al. Effectiveness of a Total Meal Replacement Program (OPTIFAST Program) on Weight Loss: Results from the OPTIWIN Study. Obesity (Silver Spring). 2019;27(1):22-9.
24. Bischoff SC, Damms-Machado A, Betz C, et al. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life – a prospective study. Int J Obesity. 2012;36:614-24. DOI:10.1038/ijo.2011.107
25. Tricò D, Moriconi D, Berta R, et al. Effects of Low-Carbohydrate versus Mediterranean Diets on Weight Loss, Glucose Metabolism, Insulin Kinetics and β-Cell Function in Morbidly Obese Individuals. Nutrients. 2021;13:1345. DOI:10.3390/nu13041345
26. Storck LJ, Meffert PJ, Rausch J, et al. Efficiency of a 15-Week Weight-Loss Program, Including a Low-Calorie Formula Diet, on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Overweight or Obesity. Obes Facts. 2021;14(1):1-11. DOI:10.1159/000511453
27. Ard JD, Neeland IJ, Rothberg AE, et al. The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study. Diabetes Obes Metab. 2024;26(3):950-60. DOI:10.1111/dom.15392
28. Meddings Maybury L, Kelly E, Dent R, Bielawska B. Сhange in alt during modified optifast weight loss program in individuals at risk for non-alcoholic fatty liver disease. J Can Assoc Gastroenterol. 2023;6(Suppl. 1):95-6. DOI:10.1093/jcag/gwac036.285
29. Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84(2):304-11.
30. Van Wissen J, Bakker N, Doodeman HJ, et al. Preoperative Methods to Reduce Liver Volume in Bariatric Surgery: a Systematic Review. Obes Surg. 2016;26(2):251-6.
31. Oster M, Hein N, Aksan A, et al. Efficacy and Safety of Intragastric Balloon Therapy Compared to a Multidisciplinary Weight Loss Program (OPTIFAST) in a Real-World Population: A Propensity Score Matching Analysis. Obes Facts. 2023;16(1):89-98. DOI:10.1159/000524895
32. Van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A, et al. Preoperative very low-calorie diet and operative outcome after laparoscopic gastric bypass: a randomized multicenter study. Arch Surg. 2011;146(11):1300-5.
2. Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104-12 (in Russian). DOI:10.14341/DM2004116-17
3. WHO European Childhood Obesity Surveillance Initiative (COSI). Available at: https://www.who.int/europe/initiatives/who-european-childhood-obesity-surveillance-initiative-(cosi). Accessed: 25.04.2024.
4. World Obesity Federation. World obesity atlas 2022. London: World Obesity Federation, 2022.
5. Ley SH, Ardisson KAV, Sun Q, et al. Contribution of the Nurses’ Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016;106(9):1624-30. DOI:10.2105/AJPH.2016.303314
6. Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311-25 (in Russian). DOI:10.26442/20751753.2021.4.200832
7. Ministerstvo zdravookhraneniia RF. Metodicheskiie rukovodstva. Standarty lechebnogo pitaniia. Moscow, 2017 (in Russian).
8. Ley SK, Andres S, Qi T, et al. Contribution of the Nurses’ Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016;106:e1-e7. DOI:10.2105/AJPH.2016.303314.
9. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521. DOI:10.3389/fendo.2023.1161521
10. Czech MP. Mechanisms of insulin resistance related to white, beige, and brown adipocytes. Mol Metab. 2020;34:27-42. DOI:10.1016/j.molmet.2019.12.014
11. Tao C, Holland WL, Wang QA, et al. Short-term versus long-term effects of adipocyte toll-like receptor 4 activation on insulin resistance in Male mice. Endocrinology. 2017;158(5):1260-70. DOI:10.1210/en.2017-00024
12. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys. 2003;419(2):101-9. DOI:10.1016/j.abb.2003.08.020
13. Frakes AE, Dillin A. The UPR: sensor and coordinator of organismal homeostasis. Mol Cell. 2017;66(6):761-71. DOI:10.1016/j.molcel.2017.05.031
14. Lalia AZ, Lanza IR. Insulin-sensitizing effects of omega-3 fatty acids: lost in translation? Nutrients. 2016;8(6):329. DOI:10.3390/nu8060329
15. Frost G, Sleeth ML, Sahuri-Arisoylu M, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611. DOI:10.1038/ncomms4611
16. Neinast M, Murashige D, Arany Z. Branched chain amino acids. Annu Rev Physiol. 2019;81:139-64. DOI:10.1146/annurev-physiol-020518-114455
17. Siddik MAB, Shin AC. Recent progress on branched-chain amino acids in obesity, diabetes, and beyond. Endocrinol Metab (Seoul Korea). 2019;34(3):234-46. DOI:10.3803/EnM.2019.34.3.234
18. Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535(7612):376-81. DOI:10.1038/nature18646
19. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541-6. DOI:10.1038/nature12506
20. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2017;2(10):747-56.
DOI:10.1016/S2468-1253(17)30147-4.
21. Grasset E, Burcelin R. The gut microbiota to the brain axis in the metabolic control. Rev Endocr Metab Disord. 2019;20(4):427-38. DOI:10.1007/s11154-019-09511-1.
22. Mustajoki P, Pekkarinen T. Very low energy diets in the treatment of obesity. Obes Rev. 2001;2(1):61-72.
23. Ard JD, Lewis KH, Rothberg A, et al. Effectiveness of a Total Meal Replacement Program (OPTIFAST Program) on Weight Loss: Results from the OPTIWIN Study. Obesity (Silver Spring). 2019;27(1):22-9.
24. Bischoff SC, Damms-Machado A, Betz C, et al. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life – a prospective study. Int J Obesity. 2012;36:614-24. DOI:10.1038/ijo.2011.107
25. Tricò D, Moriconi D, Berta R, et al. Effects of Low-Carbohydrate versus Mediterranean Diets on Weight Loss, Glucose Metabolism, Insulin Kinetics and β-Cell Function in Morbidly Obese Individuals. Nutrients. 2021;13:1345. DOI:10.3390/nu13041345
26. Storck LJ, Meffert PJ, Rausch J, et al. Efficiency of a 15-Week Weight-Loss Program, Including a Low-Calorie Formula Diet, on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Overweight or Obesity. Obes Facts. 2021;14(1):1-11. DOI:10.1159/000511453
27. Ard JD, Neeland IJ, Rothberg AE, et al. The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study. Diabetes Obes Metab. 2024;26(3):950-60. DOI:10.1111/dom.15392
28. Meddings Maybury L, Kelly E, Dent R, Bielawska B. Сhange in alt during modified optifast weight loss program in individuals at risk for non-alcoholic fatty liver disease. J Can Assoc Gastroenterol. 2023;6(Suppl. 1):95-6. DOI:10.1093/jcag/gwac036.285
29. Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84(2):304-11.
30. Van Wissen J, Bakker N, Doodeman HJ, et al. Preoperative Methods to Reduce Liver Volume in Bariatric Surgery: a Systematic Review. Obes Surg. 2016;26(2):251-6.
31. Oster M, Hein N, Aksan A, et al. Efficacy and Safety of Intragastric Balloon Therapy Compared to a Multidisciplinary Weight Loss Program (OPTIFAST) in a Real-World Population: A Propensity Score Matching Analysis. Obes Facts. 2023;16(1):89-98. DOI:10.1159/000524895
32. Van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A, et al. Preoperative very low-calorie diet and operative outcome after laparoscopic gastric bypass: a randomized multicenter study. Arch Surg. 2011;146(11):1300-5.
2. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12 [Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104-12 (in Russian)]. DOI:10.14341/DM2004116-17
3. WHO European Childhood Obesity Surveillance Initiative (COSI). Available at: https://www.who.int/europe/initiatives/who-european-childhood-obesity-surveillance-initiative-(cosi). Accessed: 25.04.2024.
4. World Obesity Federation. World obesity atlas 2022. London: World Obesity Federation, 2022.
5. Ley SH, Ardisson KAV, Sun Q, et al. Contribution of the Nurses’ Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016;106(9):1624-30. DOI:10.2105/AJPH.2016.303314
6. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., и др. Ожирение. Клинические рекомендации. Consilium Medicum. 2021;23(4):311-25 [Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311-25 (in Russian)]. DOI:10.26442/20751753.2021.4.200832
7. Министерство здравоохранения РФ. Методические руководства. Стандарты лечебного питания. M., 2017 [Ministerstvo zdravookhraneniia RF. Metodicheskiie rukovodstva. Standarty lechebnogo pitaniia. Moscow, 2017 (in Russian)].
8. Ley SK, Andres S, Qi T, et al. Contribution of the Nurses’ Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016;106:e1-e7. DOI:10.2105/AJPH.2016.303314.
9. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521. DOI:10.3389/fendo.2023.1161521
10. Czech MP. Mechanisms of insulin resistance related to white, beige, and brown adipocytes. Mol Metab. 2020;34:27-42. DOI:10.1016/j.molmet.2019.12.014
11. Tao C, Holland WL, Wang QA, et al. Short-term versus long-term effects of adipocyte toll-like receptor 4 activation on insulin resistance in Male mice. Endocrinology. 2017;158(5):1260-70. DOI:10.1210/en.2017-00024
12. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys. 2003;419(2):101-9. DOI:10.1016/j.abb.2003.08.020
13. Frakes AE, Dillin A. The UPR: sensor and coordinator of organismal homeostasis. Mol Cell. 2017;66(6):761-71. DOI:10.1016/j.molcel.2017.05.031
14. Lalia AZ, Lanza IR. Insulin-sensitizing effects of omega-3 fatty acids: lost in translation? Nutrients. 2016;8(6):329. DOI:10.3390/nu8060329
15. Frost G, Sleeth ML, Sahuri-Arisoylu M, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611. DOI:10.1038/ncomms4611
16. Neinast M, Murashige D, Arany Z. Branched chain amino acids. Annu Rev Physiol. 2019;81:139-64. DOI:10.1146/annurev-physiol-020518-114455
17. Siddik MAB, Shin AC. Recent progress on branched-chain amino acids in obesity, diabetes, and beyond. Endocrinol Metab (Seoul Korea). 2019;34(3):234-46. DOI:10.3803/EnM.2019.34.3.234
18. Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535(7612):376-81. DOI:10.1038/nature18646
19. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541-6. DOI:10.1038/nature12506
20. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2017;2(10):747-56.
DOI:10.1016/S2468-1253(17)30147-4.
21. Grasset E, Burcelin R. The gut microbiota to the brain axis in the metabolic control. Rev Endocr Metab Disord. 2019;20(4):427-38. DOI:10.1007/s11154-019-09511-1.
22. Mustajoki P, Pekkarinen T. Very low energy diets in the treatment of obesity. Obes Rev. 2001;2(1):61-72.
23. Ard JD, Lewis KH, Rothberg A, et al. Effectiveness of a Total Meal Replacement Program (OPTIFAST Program) on Weight Loss: Results from the OPTIWIN Study. Obesity (Silver Spring). 2019;27(1):22-9.
24. Bischoff SC, Damms-Machado A, Betz C, et al. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life – a prospective study. Int J Obesity. 2012;36:614-24. DOI:10.1038/ijo.2011.107
25. Tricò D, Moriconi D, Berta R, et al. Effects of Low-Carbohydrate versus Mediterranean Diets on Weight Loss, Glucose Metabolism, Insulin Kinetics and β-Cell Function in Morbidly Obese Individuals. Nutrients. 2021;13:1345. DOI:10.3390/nu13041345
26. Storck LJ, Meffert PJ, Rausch J, et al. Efficiency of a 15-Week Weight-Loss Program, Including a Low-Calorie Formula Diet, on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Overweight or Obesity. Obes Facts. 2021;14(1):1-11. DOI:10.1159/000511453
27. Ard JD, Neeland IJ, Rothberg AE, et al. The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study. Diabetes Obes Metab. 2024;26(3):950-60. DOI:10.1111/dom.15392
28. Meddings Maybury L, Kelly E, Dent R, Bielawska B. Сhange in alt during modified optifast weight loss program in individuals at risk for non-alcoholic fatty liver disease. J Can Assoc Gastroenterol. 2023;6(Suppl. 1):95-6. DOI:10.1093/jcag/gwac036.285
29. Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84(2):304-11.
30. Van Wissen J, Bakker N, Doodeman HJ, et al. Preoperative Methods to Reduce Liver Volume in Bariatric Surgery: a Systematic Review. Obes Surg. 2016;26(2):251-6.
31. Oster M, Hein N, Aksan A, et al. Efficacy and Safety of Intragastric Balloon Therapy Compared to a Multidisciplinary Weight Loss Program (OPTIFAST) in a Real-World Population: A Propensity Score Matching Analysis. Obes Facts. 2023;16(1):89-98. DOI:10.1159/000524895
32. Van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A, et al. Preoperative very low-calorie diet and operative outcome after laparoscopic gastric bypass: a randomized multicenter study. Arch Surg. 2011;146(11):1300-5.
________________________________________________
2. Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104-12 (in Russian). DOI:10.14341/DM2004116-17
3. WHO European Childhood Obesity Surveillance Initiative (COSI). Available at: https://www.who.int/europe/initiatives/who-european-childhood-obesity-surveillance-initiative-(cosi). Accessed: 25.04.2024.
4. World Obesity Federation. World obesity atlas 2022. London: World Obesity Federation, 2022.
5. Ley SH, Ardisson KAV, Sun Q, et al. Contribution of the Nurses’ Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016;106(9):1624-30. DOI:10.2105/AJPH.2016.303314
6. Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311-25 (in Russian). DOI:10.26442/20751753.2021.4.200832
7. Ministerstvo zdravookhraneniia RF. Metodicheskiie rukovodstva. Standarty lechebnogo pitaniia. Moscow, 2017 (in Russian).
8. Ley SK, Andres S, Qi T, et al. Contribution of the Nurses’ Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016;106:e1-e7. DOI:10.2105/AJPH.2016.303314.
9. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521. DOI:10.3389/fendo.2023.1161521
10. Czech MP. Mechanisms of insulin resistance related to white, beige, and brown adipocytes. Mol Metab. 2020;34:27-42. DOI:10.1016/j.molmet.2019.12.014
11. Tao C, Holland WL, Wang QA, et al. Short-term versus long-term effects of adipocyte toll-like receptor 4 activation on insulin resistance in Male mice. Endocrinology. 2017;158(5):1260-70. DOI:10.1210/en.2017-00024
12. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys. 2003;419(2):101-9. DOI:10.1016/j.abb.2003.08.020
13. Frakes AE, Dillin A. The UPR: sensor and coordinator of organismal homeostasis. Mol Cell. 2017;66(6):761-71. DOI:10.1016/j.molcel.2017.05.031
14. Lalia AZ, Lanza IR. Insulin-sensitizing effects of omega-3 fatty acids: lost in translation? Nutrients. 2016;8(6):329. DOI:10.3390/nu8060329
15. Frost G, Sleeth ML, Sahuri-Arisoylu M, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611. DOI:10.1038/ncomms4611
16. Neinast M, Murashige D, Arany Z. Branched chain amino acids. Annu Rev Physiol. 2019;81:139-64. DOI:10.1146/annurev-physiol-020518-114455
17. Siddik MAB, Shin AC. Recent progress on branched-chain amino acids in obesity, diabetes, and beyond. Endocrinol Metab (Seoul Korea). 2019;34(3):234-46. DOI:10.3803/EnM.2019.34.3.234
18. Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535(7612):376-81. DOI:10.1038/nature18646
19. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541-6. DOI:10.1038/nature12506
20. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2017;2(10):747-56.
DOI:10.1016/S2468-1253(17)30147-4.
21. Grasset E, Burcelin R. The gut microbiota to the brain axis in the metabolic control. Rev Endocr Metab Disord. 2019;20(4):427-38. DOI:10.1007/s11154-019-09511-1.
22. Mustajoki P, Pekkarinen T. Very low energy diets in the treatment of obesity. Obes Rev. 2001;2(1):61-72.
23. Ard JD, Lewis KH, Rothberg A, et al. Effectiveness of a Total Meal Replacement Program (OPTIFAST Program) on Weight Loss: Results from the OPTIWIN Study. Obesity (Silver Spring). 2019;27(1):22-9.
24. Bischoff SC, Damms-Machado A, Betz C, et al. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life – a prospective study. Int J Obesity. 2012;36:614-24. DOI:10.1038/ijo.2011.107
25. Tricò D, Moriconi D, Berta R, et al. Effects of Low-Carbohydrate versus Mediterranean Diets on Weight Loss, Glucose Metabolism, Insulin Kinetics and β-Cell Function in Morbidly Obese Individuals. Nutrients. 2021;13:1345. DOI:10.3390/nu13041345
26. Storck LJ, Meffert PJ, Rausch J, et al. Efficiency of a 15-Week Weight-Loss Program, Including a Low-Calorie Formula Diet, on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Overweight or Obesity. Obes Facts. 2021;14(1):1-11. DOI:10.1159/000511453
27. Ard JD, Neeland IJ, Rothberg AE, et al. The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study. Diabetes Obes Metab. 2024;26(3):950-60. DOI:10.1111/dom.15392
28. Meddings Maybury L, Kelly E, Dent R, Bielawska B. Сhange in alt during modified optifast weight loss program in individuals at risk for non-alcoholic fatty liver disease. J Can Assoc Gastroenterol. 2023;6(Suppl. 1):95-6. DOI:10.1093/jcag/gwac036.285
29. Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84(2):304-11.
30. Van Wissen J, Bakker N, Doodeman HJ, et al. Preoperative Methods to Reduce Liver Volume in Bariatric Surgery: a Systematic Review. Obes Surg. 2016;26(2):251-6.
31. Oster M, Hein N, Aksan A, et al. Efficacy and Safety of Intragastric Balloon Therapy Compared to a Multidisciplinary Weight Loss Program (OPTIFAST) in a Real-World Population: A Propensity Score Matching Analysis. Obes Facts. 2023;16(1):89-98. DOI:10.1159/000524895
32. Van Nieuwenhove Y, Dambrauskas Z, Campillo-Soto A, et al. Preoperative very low-calorie diet and operative outcome after laparoscopic gastric bypass: a randomized multicenter study. Arch Surg. 2011;146(11):1300-5.
Авторы
Е.А. Трошина, К.А. Комшилова*, Н.В. Силина, Е.В. Ершова, Ф.Х. Дзгоева
ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*Komshilova.Kseniya@endocrincentr.ru
Endocrinology Research Centre, Moscow, Russia
*Komshilova.Kseniya@endocrincentr.ru
ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*Komshilova.Kseniya@endocrincentr.ru
________________________________________________
Endocrinology Research Centre, Moscow, Russia
*Komshilova.Kseniya@endocrincentr.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.